Saga Ventures

Saga Ventures is a venture capital firm whose website carries the line "Investing in what's next." A Business Wire release on the Hike Medical financing describes Max Altman as co-founder and managing partner of Saga Ventures.^[1],[2]

Saga Ventures publishes company stories on its website, written by Thomson Nguyen, about investments including Dedalus Labs and Profound. The pages we could read do not state a check size, stage focus, headquarters or founding year.^[1]

Saga Ventures has led rounds in insurance and healthcare companies. It led the Series C of home-insurance company Stand and the seed and Series A round of orthotics and prosthetics company Hike Medical, and it joined a strategic round in Promise, a generative AI studio.^[3],[2],[4]

Saga Ventures I, LP is a Delaware limited partnership organized in 2024 that registered a venture capital fund offering with the SEC on Form D. The filing lists a total offering amount of $125,000,000, with $0 sold and the first sale yet to occur.^[5],[6],[7]

Saga Ventures II, LP is a Delaware limited partnership organized in 2026 as a venture capital fund. Its Form D lists a total offering amount of $225,000,000, with $0 sold and the first sale yet to occur.^{[6],[5],[7],[8]}

Saga Ventures Saria, LP was organized in 2025, according to its Form D. The filing lists a total offering amount of $3,000,000, reports $3,000,000 sold, and gives April 17, 2025 as the date of first sale.^[9]

Saga Ventures Epona, LP was organized in 2026, according to its Form D. The filing lists a total offering amount of $35,000,000 and $0 sold.^{[7],[5],[6],[8]}

Saga Ventures Mido, LP was organized in 2026, according to its Form D. The filing lists a total offering amount of $5,000,000, reports $5,000,000 sold, and gives 2026-10-06 as the date of first sale.^[8],[6],[7]

Saga Ventures' Form D offering amounts are targets set by the issuer, and the amounts sold are as the issuer reported them. The Epona filing reports a first-sale date of 2026-03-30 alongside $0 sold, an inconsistency we have not resolved, so none of these figures is stated as committed capital or fund size.^{[7],[5],[6],[8]}

Saga Ventures co-founder and managing partner Max Altman led Hike Medical's round, according to the company's Business Wire release. The release quotes Altman as co-founder and managing partner at Saga Ventures.^[2]

Saga Ventures I, LP's Form D lists Max Altman, Thomson Nguyen and Ben Braverman each as a Managing Director of the General Partner of the Issuer. Ben Braverman is named as a Managing Director of the General Partner in every Saga Ventures filing we opened, Thomson Nguyen in all but the Mido filing, and Max Altman in all but the Epona filing.^{[5],[6],[9],[7],[8]}

Saga Ventures' website attributes its company stories to Thomson Nguyen. His post on Profound says Saga led Profound's seed round and that Kleiner Perkins invested in the Series A.^[1]

Saga Ventures' website displays an unlabeled list of company names that includes Profound, Anduril, Owner.com, Stand, Mercury, Merge Labs, Hike Medical, Fleetworks, Dedalus Labs, Ragie, Vapi, Slope and Sett. The list also includes Campuswire, Luminal and Monaco, and the site does not say what role Saga played in each.^[1]

Saga Ventures led Stand's $70 million Series C at a $1 billion valuation, according to a paid PR Newswire release dated October 15, 2026. Lowercarbon, Eclipse, Equal Ventures, Inspired Capital, Neotribe and Jackson Square Ventures participated, and the release says the round brings total raised to $130M.^{[3],[6],[7],[8]}

Saga Ventures' Max Altman led Hike Medical's $22.5 million seed and Series A funding, announced in a Business Wire release dated August 25, 2026. Indicator Ventures, Fifth Down Capital and RiverPark Ventures also participated.^{[2],[6],[7],[8]}

Saga Ventures says on its website that it partnered with Dedalus Labs, which builds infrastructure for deploying MCP servers, alongside Y Combinator and Kindred Ventures. In the Profound post, Saga says it led Profound's seed round, and the firm describes Kleiner Perkins as having leaned in for the Series A.^[1]